 |
A newly published article introduces us to a new formulation of Azelaic Acid known as Azeloglicina. Azeloglicina (chemical name Potassium Azeloyl Diglycinate) is described as a “condensation product between one mole of Azelaic Acid and two moles of Glycine” and is touted as an improvement over the individual properties of both. A company called Singerga holds the patent on Azeloglicina.
The study showed, after 4 weeks of use, improvements in redness and hydration as well as some improvements in flushing, stinging, and burning. Very early days though of course with a small trial and so far unquantified benefits.
It appears that Azeloglicina is also being promoted as a skin lightening product.
According to Sinerga;
Azelaic acid is widely know for its antibacterial, sebum-normalizing and keratoplastic capabilities and is normally used in 15-20% concentrations; it may cause, as a consequence of its activity on sebum reduction and modulation of skin proliferation, skin dryness and irritation.
Another important application of Azelaic Acid in dermatology is due to its bacteriostatic activity: azelaic acid has bacteriostatic properties versus aerobic and anaerobic. This activity is probably due to the inhibition of cells’ proteic synthesis, while it also performs a reduction of free fatty acids in cutaneous sebum due to a competitive inhibition of the enzyme 5-α reductase
DERMATOLOGICAL USES
The possibility to modify the molecule of Azelaic acid and increase the moisturizing and anti inflammatory properties can be regarded has an important breakthrough in the development of the molecule. Indeed, new application fields can be identified in the light of new therapeutic uses of azelaic acid such as in rosacea.
New Abstract
J Cosmet Dermatol. 2012 Mar;11(1):37-41.
Berardesca E, Iorizzo M, Abril E, Guglielmini G, Caserini M, Palmieri R, Piérard GE.,
San Gallicano Dermatological Institute, Rome, Italy Private Practice, Dermatology, Lugano, Switzerland Scientific/Regulatory Affairs Department, Sinerga S.p.A., Milan, Italy Scientific Department, Polichem SA, Lugano, Switzerland Department of Dermatopathology, University Hospital of Liège, Liège, Belgium.
Background: Rosacea is a chronic inflammatory skin disease affecting mostly facial skin. Its origin is multifactorial. Important steps in its treatment are avoidance of any triggering factor and control of skin inflammation.
Aim: To assess the benefit of topical applications of a new product (P-3075).
Patients/Methods: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, pilot study was carried out to evaluate the efficacy and tolerability of a cream (P-3075) based on 5% potassium azeloyl diglycinate (PAD, Azeloglicina) and 1% hydroxypropyl chitosan (HPCH).
Forty-two patients (rosacea stages I and II) were enrolled and randomized, 28 in the P-3075 group and 14 in the placebo group.
They were asked to apply the cream twice daily for 4 weeks.
The main assessments were the objective quantification of erythema and skin hydration using the Mexameter and Corneometer devices, respectively.
Clinical signs and symptoms were evaluated on a four-point scale.
Results: The P-3075 cream applied for 28 days was effective in skin protection by reducing erythema, evaluated both instrumentally and clinically.
In addition, the clinical assessments of other symptoms such as flushing, stinging, and burning supported the beneficial effect of the P-3075 cream.
Conclusions: The anti-inflammatory and moisturizing effects of potassium azeloyl diglycinate combined with the protective properties of HPCH allow the new product to be a good candidate for controlling signs and symptoms of rosacea.
